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ABSTRACT 
Background  Influenza is associated with an increased risk for cardiovascular events in patients 
with heart failure. 
Objectives To examine the prevalence and predictors of influenza vaccination among 
participants in the PARADIGM-HF study and to investigate associations between receiving 
influenza vaccine and cardiovascular death or heart failure hospitalizations, all-cause 
hospitalizations, and cardiopulmonary or influenza-related hospitalizations. 
Methods  We utilized data from the Prospective Comparison of ARNI with ACEI to 
Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, 
in which patients with heart failure were randomized to the angiotensin receptor-neprilysin 
inhibitor LCZ696 (sacubitril/valsartan) or enalapril. We assessed predictors of receiving 
influenza vaccination, and assessed the relationship between influenza vaccination and outcomes 
in a propensity-adjusted model.  
Results  Out of 8099 study participants, 1769 (21%) received influenza vaccination. We 
observed significant regional variation in vaccination rates, with highest rates in the Netherlands 
(77.5%), Great Britain (77.2%), and Belgium (67.5%) and lowest rates in Asia (2.6%), with 
intermediate rates in North America (52.8%). Top predictors of vaccination included enrolling 
country, white race, implanted defibrillator, older age, lower New York Heart Association 
functional class, lower heart rate, and a history of diabetes mellitus. Influenza vaccination was 
associated with a reduced risk for all-cause mortality in propensity adjusted (HR 0.81, 95% CI 
[0.67, 0.97, p=0.015) models.  
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Conclusions  Influenza vaccination rates varied widely in patients with heart failure with 
reduced ejection fraction enrolled in the PARADIGM-HF trial, and vaccination was associated 
with reduced risk for death, although whether this association was causal cannot be determined.  
Key words: Chronic heart failure, influenza vaccination, clinical trial 
ABBREVIATIONS 
NYHA FC = New York Heart Association Functional Class 
ARNI = angiotensin receptor neprilysin inhibitor 
ACEi = angiotensin converting enzyme inhibitor 
ARB = angiotensin receptor blocker 
eGFR = estimated glomerular filtration rate  
BMI = body mass index 
ICD = implantable cardioverter defibrillator 
CRT = cardiac resynchronization therapy  
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INTRODUCTION 
Influenza infection can be devastating for patients with cardiovascular disease, and leads 
to significant morbidity and mortality each year.1-4 Influenza vaccination is recommended 
annually for patients with cardiovascular disease by both the Centers for Disease Control and 
Prevention, the American Heart Association, and the European Center for Disease Prevention 
and Control.5,6 A meta-analysis of randomized, controlled studies has shown that receiving 
influenza vaccination reduced the risk for major adverse cardiovascular events in patients with 
coronary artery disease compared to no vaccination.7  
Although widely recognized as beneficial, vaccination rates in patients with heart failure 
vary widely in the United States and across the world.8 Heart failure patients are especially 
susceptible to influenza-related complications including acute heart failure exacerbations and 
secondary infections such as pneumonia, both of which increase hospitalizations.4,9   
The Prospective Comparison of ARNI with ACEI to Determine Impact on Global 
Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial10 enrolled patients with 
symptomatic heart failure with reduced ejection fraction and randomly allocated them to receive 
the angiotensin receptor neprilysin inhibitor LCZ696 (sacubitril/valsartan) or enalapril. At the 
time of enrollment, participants were queried about receipt of influenza vaccination in the past 
12 months. We utilized data from PARADIGM-HF to assess prevalence of and baseline factors 
associated with influenza vaccination, as well as outcomes in those who did and did not receive 
influenza vaccination. We hypothesized that influenza vaccination would be associated with 
reduced risk for hospitalizations and mortality in patients with heart failure after propensity 
adjustment.  
METHODS 
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Study Design and Patient Selection 
PARADIGM-HF was a double blind, randomized, active controlled trial designed to 
assess the impact of the angiotensin receptor neprilysin inhibitor LCZ696 (sacubitril/valsartan) 
compared with enalapril on cardiovascular mortality and heart failure hospitalizations in patients 
with LVEF ≤ 40% and New York Heart Association (NYHA) Functional Class II-IV HF. 
Eligible subjects had elevated natriuretic peptide levels and were treated with stable doses of 
angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and 
beta adrenergic receptor blockers for at least 4 weeks prior to trial enrollment. Patients with 
symptomatic hypotension, estimated glomerular filtration rate (eGFR) less than 30 
ml/min/1.73m2, potassium concentration > 5.2 mmol/L at screening, or history of angioedema 
were excluded. The study design and detailed inclusion and exclusion criteria have been 
previously reported.11 
Participants underwent two back-to-back single blind run-in phases with enalapril at a 
dose of at least 10mg twice daily for 2 weeks, followed by LCZ696 (sacubitril/valsartan), first 
dosed at 100mg twice daily, then 200mg twice daily for 4-6 weeks. Participants were then 
randomized to receive enalapril 10mg twice daily or LCZ696 (sacubitril/valsartan) 200mg twice 
daily. Participants were followed for a median duration of 27 months. Participants were asked if 
they received the seasonal influenza vaccine during the previous 12 months, and this information 
was recorded in the case report form. Cardiopulmonary and influenza-related hospitalizations 
were captured through investigator reporting of cause of hospitalization on the case report form. 
The protocol was approved at each participating site by an ethics committee or institutional 
review board. All participants provided written informed consent in accordance with established 
guidelines for the protection of human subjects. 
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Statistical Analyses 
In order to identify potential differences, baseline characteristics were compared between 
participants who received influenza vaccination and those who did not. Between-group 
assessments were performed using t-tests for continuous variables, and chi-square or Fisher’s 
exact tests, as appropriate, for categorical variables. Logistic regression models were used to 
examine associations between baseline characteristics and receipt of influenza vaccination, 
adjusting for treatment assignment and the following covariates: age, sex, race, country, body 
mass index, ejection fraction, eGFR, New York Heart Association functional class, history of 
diabetes mellitus, myocardial infarction, respiratory disease, and use of ACE inhibitors or ARBs, 
beta adrenergic blockers, mineralocorticoid receptor antagonists, and diuretics at screening. A 
propensity score was created for receipt of influenza vaccination based on the logistic regression 
model. For the analysis of multivariable predictors of vaccination, country was included as a 
continuous covariate, represented by the observed overall vaccination rate of each participant’s 
home country, rather than country on its own. As an exploratory analysis, we utilized each 
country’s per-capita gross domestic product (GDP) as a continuous variable in the multivariable 
model. Cox proportional hazards models were constructed to investigate associations of 
influenza vaccination with the risk for all-cause mortality, cardiovascular death or heart failure 
hospitalization, all-cause hospitalizations, and cardiopulmonary or influenza-related 
hospitalizations, unadjusted as well as in propensity-matched models. The propensity models 
were implemented by creating 100 equally sized groups of patients based on their estimated 
propensity for having received influenza vaccination, as described above. These groups were 
subsequently used as a stratification factor in the Cox model, so that the reported hazard refers to 
the comparison of vaccinated and unvaccinated patients within the same propensity stratum. We 
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performed a sensitivity analysis examining the association of influenza vaccine receipt and 
clinical outcomes, censoring events at 12 months since we did not have data on vaccination after 
randomization. A p-value of <0.05 was considered statistically significant. All analyses were 
completed using Stata, version 13 (StataCorp LP, College Station, TX). 
RESULTS 
Out of 8399 participants in the PARADIGM-HF trial, 1769 (21%) received influenza 
vaccination within a 12 month period while enrolled in the study. Baseline characteristics by 
influenza vaccination status are shown in Table 1. Influenza vaccine recipients were significantly 
older, had higher BMI, lower NYHA functional class and eGFR, and were more likely to be 
male and Caucasian. More vaccine recipients had a history of diabetes, myocardial infarction, 
were taking beta-blockers, and had received cardiac resynchronization therapy, and less were 
taking mineralocorticoid receptor antagonists. There was significant variation in vaccination 
rates by country (Table 2), with vaccination rates highest in the Netherlands (77.5%) the United 
Kingdom (77.2%), and Belgium (67.5%), and lowest in Asia (2.6%)(Table 2). 
In a multivariable regression model, significant predictors of receiving influenza vaccine 
included, in descending order of association: country, older age, history of diabetes mellitus, 
lower NYHA functional class, lower heart rate, use of digoxin, use of an ICD or CRT, lower 
eGFR, higher ejection fraction, white race, and history of hospitalization for heart failure (Table 
3). In an exploratory analysis, we observed a correlation between vaccination rates and country-
specific GDP data (supplementary figure 1). 
Influenza vaccination was associated with a lower risk for all-cause mortality compared 
to no vaccination in unadjusted models (Figure 1) and after adjusting for the propensity to 
receive influenza vaccine (HR 0.81, 95% CI [0.67, 0.97], p=0.015). In contrast, vaccination was 
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associated with increased rates of cardiopulmonary, influenza-related, and all-cause 
hospitalization in unadjusted models, but not in propensity-adjusted models (Table 4). Sensitivity 
analyses censoring events at 12 months post randomization revealed similar results (data not 
shown). The overall benefit of LCZ696 (sacubitril/valsartan) over enalapril on the trial’s primary 
outcome was maintained regardless of influenza vaccination (p-interaction = 0.31).  
DISCUSSION 
 In patients with heart failure and reduced ejection fraction enrolled in the PARADIGM-
HF study, we found substantial world-wide regional variation in influenza vaccination rates, with 
rates substantially higher in Western Europe, the United States, and Canada compared to Asia. 
However, even in the United States, despite strong recommendations from the CDC and a 
science advisory statement published by the American Heart Association advocating for annual 
vaccination, vaccination rates were only 53% in this high-risk population.5,12 Aside from 
country, the most significant predictors of vaccination included older age, history of diabetes 
mellitus, lower NYHA functional class, lower heart rate, use of digoxin, and use of either an ICD 
or CRT therapy. Influenza vaccination was associated with lower all-cause mortality even when 
adjusted for the propensity to receive influenza vaccine. Vaccination did not affect the efficacy 
of LCZ696 (sacubitril/valsartan). 
 There are limited data on influenza vaccination rates in patients with heart failure 
worldwide. Even in the United States, influenza vaccination rates in patients with heart failure 
have ranged from 25% to approximately 76%, depending on the population studied.13-15 In one 
study of patients with heart failure who were mostly indigent or had Medicare or Medicaid, 
baseline rates were 28.3% prior to a vaccination campaign program, and improved to 50.3% after 
the program.14 In an analysis of the impact of American Heart Association’s Get With The 
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Guidelines–Heart Failure (GWTG-HF) “Plus” program, which recognized hospitals for 
additional quality measures such as influenza vaccination, the increase in influenza vaccination 
rates slowed following program implementation compared to years leading up to the program, 
although baseline vaccination rates were greater than 50%.13 The reasons for poor influenza 
vaccine uptake in the heart failure population remain unclear, but include factors such as reduced 
accessibility to vaccination clinics in rural areas, cost of vaccination if uninsured or if 
vaccination programs are not offered through employers, limited knowledge regarding the 
benefits of vaccination, mistrust of ingredients contained in the vaccine, or the misconception 
that influenza vaccination will cause influenza infection.14,16  
 We found that the most important factor influencing vaccination was country. We 
observed low vaccination rates among Asians as previously reported, which may be due to 
factors such as competing health care priorities and inadequate resources, particularly in 
developing countries, incomplete region-specific data regarding influenza vaccine effectiveness, 
or differing practice patterns between regions.17-19 Older age, white race and concomitant 
diabetes mellitus were also significant predictors of vaccination, potentially due to increased 
health care utilization or improved access to health care.20 Country specific GDP appeared to be 
associated with per-country vaccination rates, suggesting that socioeconomic status may play a 
role in vaccination, although these findings should be interpreted with caution, as we did not 
have participant-specific socioeconomic data and these factors can vary widely within countries.  
 We found that patients who received influenza vaccination had lower all-cause mortality, 
even when adjusting for the propensity to receive vaccination. This finding is consistent with 
other observational studies that have similarly reported lower rates of death in individuals 
receiving influenza vaccination, including a retrospective analysis of over 100,000 patients with 
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heart failure from the Veterans Health Administration,15 and a prospective cohort analysis of 
patients hospitalized for heart failure.21 Despite the adjustment for the propensity to receive 
influenza vaccine, the observed association between influenza vaccination and lower mortality 
may simply be indicative of better access to health care, improved surveillance, or ambulatory 
independence of vaccine recipients, and does not prove that influenza vaccination reduces 
mortality in this population. As we observed substantial differences between those who did and 
did not receive vaccine, we cannot rule out the possibility that unmeasured confounding for 
which we are not able to adjust may contribute to the observed findings among influenza vaccine 
recipients.  
 That influenza vaccination was associated with a higher unadjusted rate of hospitalization 
of any type, but not an increased risk of death, suggests that in PARADIGM-HF, influenza 
vaccination was a potential surrogate for higher level of and improved access to health care, 
evidenced by more hospitalizations, for any given severity of illness, among individuals who 
received influenza vaccine. The fact that the risk for hospitalization was substantially altered 
following propensity adjustment implies that factors that influence the likelihood of vaccination 
might also influence rates of hospitalization.  Nevertheless, other large, but more geographically 
homogenous, observational studies have shown associations between influenza vaccination and 
reduced risk for hospitalizations.22,23  
 Several additional limitations of this analysis should be noted. First, we only had 
vaccination information during a 12 month period in the trial, and as such could not examine 
associations between multiple year receipt of influenza vaccination and clinical outcomes, as 
these data were not collected. Influenza vaccination history was collected by site personnel via a 
case report form, and may be subject to recall bias. Additionally, we did not collect information 
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about the type of vaccine participants received (high dose, quadrivalent, adjuvant), therefore we 
were not able to explore whether certain vaccine formulations were more strongly associated 
with better outcomes. Patients with heart failure exhibited blunted immune responses to standard 
dose trivalent influenza vaccination in previous studies,24,25 and use of a higher dose of influenza 
vaccine resulted in enhanced antibody titers compared to a standard dose formulation.26 
However, the vaccine formulation that portends the greatest protection against influenza-related 
complications remains unclear.  
 In conclusion, in a cohort of patients with heart failure and reduced ejection fraction who 
were well managed on guideline directed medical therapy, we observed significant regional 
variation in rates of influenza vaccination, despite well publicized recommendations from public 
health organizations advocating for annual immunization in this high risk population. Recipients 
of influenza vaccination tended to be older, of Caucasian heritage, and more commonly had 
other co-morbidities that may necessitate closer medical follow up. Influenza vaccination did not 
affect the efficacy of LCZ696, but was associated with lower all-cause mortality, even after 
adjustment for the propensity to receive influenza vaccination, although whether this association 
was causal cannot be determined from these observational data.  
CLINICAL COMPETENCIES 
Medical Knowledge: influenza vaccination is recommended on an annual basis in patients with 
heart failure and may be associated with reduced mortality. 
Patient Care: Health care providers should educate patients on the benefits of annual influenza 
vaccination and provide opportunities for vaccination in clinic settings.  
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Translational outlook 1: Future studies should examine associations between multiple year 
influenza vaccination and cardiovascular outcomes in patients with heart failure.  
Translational outlook 2: Although annual influenza vaccination is recommended by clinical 
guidelines, it is not known which specific influenza vaccine (trivalent, high dose, quadrivalent) 
may be most beneficial in this high-risk population. 
Translational outlook 3: The exact mechanisms by which influenza vaccination may lead to 
improved outcomes in patients with heart failure requires further study 
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FIGURE LEGEND 
Figure 1. Crude and propensity adjusted hazard ratio for all-cause death, cardiovascular death or 
heart failure hospitalization (primary endpoint), all-cause hospitalization, and 
cardiopulmonary/influenza-related hospitalization or death. 
Table 1. Baseline characteristics by influenza vaccine use 
Characteristic  No influenza vaccination 
N=6630 (79%) 
Influenza vaccination 
N=1769 (21%) 
p-value 
Age 62.7 ± 11.5 67.9 ± 10.1 p < 0.0001 
Female sex (%) 1481 (22.3%) 351 (19.8%) p = 0.024 
Caucasian Race 4008 (60.5%) 1536 (86.8%) p<0.0001 
Body mass index 27.93 ± 5.50 29.06 ± 5.51 p<0.0001 
Ischemic etiology 3949 (59.6%) 1087 (61.4%) p=0.15 
NYHA FC 
I 
II 
III 
IV 
 
306 (4.6%) 
4569 (69.0%) 
1694 (25.6%) 
52 (0.8%) 
 
83 (4.7%) 
1350 (76.5%) 
324 (18.4%) 
8 (0.5%) 
p<0.0001 
Left ventricular 
ejection fraction 
29.53 ± 6.17 29.32 ± 6.41 p=0.1968 
History of heart failure 
hospitalization  
4267 (64.4%) 1007 (56.9%) P<0.0001 
History of hypertension 4722 (71.2%) 1218 (68.9%) p=0.052 
History of diabetes 2184 (32.9%) 723 (40.9%) p<0.0001 
History of myocardial 
infarction 
2761 (41.6%) 873 (49.3%) p<0.0001 
Use of ICD 667 (10.1%) 576 (32.6%) p<0.0001 
Use of CRT 305 (4.6%) 269 (15.2%) p<0.0001 
Baseline medications 
ACE inhibitors 
ARBs 
Beta blockers 
MRAs 
Diuretic 
Digoxin 
 
5120 (77.2%) 
1519 (22.9%) 
6139 (92.6%) 
3817 (57.6%) 
5307 (80.0%) 
2100    (31.7%) 
 
1412 (79.8%) 
373 (21.1%) 
1672 (94.5%) 
854 (48.3%) 
1431 (80.9%) 
439 (24.8%) 
 
p=0.02 
p=0.10 
p=0.005 
p<0.0001 
p=0.43 
p<0.0001 
eGFR 69.5 ± 19.5 63.1 ± 17.9 p<0.0001 
NT-proBNP 2967.5 ± 4121.7 2641.7 ± 3420.0 p=0.002 
 
Table 2. Vaccination rate by country 
Country Percent 
Argentina 30.2 
Belgium 67.6 
Bulgaria 1.4 
Brazil 29.7 
Canada 47.0 
Chile 44.1 
China 0.6 
Columbia 7.3 
Czechoslovakia 10.0 
Germany 37.1 
Denmark 54.7 
Dominican Republic 0 
Ecuador 7.8 
Spain 52.8 
Estonia 3.4 
Finland 60.0 
France 39.1 
Great Britain 77.2 
Guatemala 2.9 
Hong Kong 8.7 
Hungary 22.7 
India 0.2 
Iceland 55.6 
Israel 36.6 
Italy 41.0 
Korea 20.7 
Lithuania 0 
Latvia 0 
Mexico 17.5 
Malaysia 0 
Netherlands 77.5 
Panama 13.3 
Peru 0 
Philippines 4.0 
Poland 4.6 
Portugal 53.1 
Romania 4.4 
Russia 0.2 
Singapore 9.3 
Slovakia 14.3 
Sweden 55.2 
Thailand 0 
Turkey 1.6 
Taiwan 5.8 
USA 55.1 
Venezuela 0 
South Africa 6.2 
 
Table 3. Predictors of Receipt of Influenza Vaccine 
Predictor Z score Odds Ratio (95% CI) 
Country  31.8 1.79 (1.72, 1.85) 
Age 7.32 1.02 (1.02, 1.04) 
History of diabetes mellitus 4.16 1.35 (1.17, 1.55) 
NYHA functional class  3.38 0.79 (0.68, 0.90) 
Heart rate 2.51 0.99 (0.986, 0.998) 
Use of digoxin  2.51 1.22 (1.04, 1.43) 
Use of an ICD 2.37 1.33 (1.02, 1.47) 
Use of CRT 2.18 1.22 (1.05, 1.69) 
eGFR 2.18 0.995 (0.992, 1.0) 
Ejection fraction  2.06 1.01 (1.0, 1.02) 
White race  2.01 1.21 (1.0, 1.45) 
History of hospitalization for 
heart failure  
1.98 0.87 (0.76, 1.0) 
*Other model covariates which were not significant included: history of myocardial infarction, 
left ventricular ejection fraction, blood pressure, sex, body mass index, use of ACE inhibitor, 
ARB, beta blocker, MRA, or diuretic, NT-proBNP, and BNP. 
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Table 4. Association between influenza vaccination and outcomes 
 Unadjusted Propensity Adjusted 
Outcome HR 95% CI HR 95% CI 
Death 0.81 0.71, 0.92 0.82 0.70, 0.96 
Cardiovascular death or 
heart failure hospitalization 
0.91 0.81, 1.01 0.93 0.81, 1.06 
Cardiopulmonary or 
influenza-related 
hospitalization or death 
1.11 1.02, 1.20 0.99 0.89, 1.10 
All-cause hospitalization 1.50 1.39, 1.61 1.07 0.97, 1.18 
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